Ibopamine

Last updated
Ibopamine
Ibopamine.svg
Clinical data
AHFS/Drugs.com International Drug Names
ATC code
Identifiers
  • 5-[2-(methylamino)ethyl]-2-[(2-methylpropanoyl)oxy]phenyl 2-methylpropanoate
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
CompTox Dashboard (EPA)
ECHA InfoCard 100.060.189 OOjs UI icon edit-ltr-progressive.svg
Chemical and physical data
Formula C17H25NO4
Molar mass 307.390 g·mol−1
3D model (JSmol)
  • O=C(Oc1cc(ccc1OC(=O)C(C)C)CCNC)C(C)C
  • InChI=1S/C17H25NO4/c1-11(2)16(19)21-14-7-6-13(8-9-18-5)10-15(14)22-17(20)12(3)4/h6-7,10-12,18H,8-9H2,1-5H3 X mark.svgN
  • Key:WDKXLLJDNUBYCY-UHFFFAOYSA-N X mark.svgN
 X mark.svgNYes check.svgY  (what is this?)    (verify)

Ibopamine is a sympathomimetic drug, designed as a prodrug of epinine (deoxyepinephrine or N-methyldopamine), used in ophthalmology. [1] It induces mydriasis. [2] It also has been investigated for use in the treatment of congestive heart failure. [3]

Contents

It acts on D1 [4] [5] and α-adrenergic receptors as an agonist. [6]

Ibopamine was first prepared by Casagrande and co-workers. [7]

Instilled at 2% concentration, ibopamine exhibits several functions at ocular level such as pre- and post-operative mydriatic activity, D1 dopaminergic activity, etc. [6]

Pharmacokinetics

Due to the esterases existing in the aqueous humour and ocular tissues, ibopamine can be rapidly hydrolysed to epinine which is the active molecule responsible for the mydriatic effect. [8] The epinine, an analogue of dopamine, can stimulate dopamine receptors and to a lesser degree adrenergic receptors. [9] Thus it is believed that epinine is the pharmacologically active moiety. It has been shown that the half-life of ibopamine is short to about 2 minutes in the aqueous humour owing to the fast hydrolysis. [10] So ibopamine can not be found in the aqueous humor after instillation.

Pharmacodynamics

After being hydrolysed to epinine, ibopamine is able to stimulate the alpha-adrenergic and D1 dopaminergic receptors, thereby exhibiting mydriatic effects. [11] In some randomized clinical trials, the D1 dopaminergic activity of ibopamine led to an increased production of aqueous humour and intraocular pressure (IOP) in primary open-angle glaucoma (POAG) patients. [12]

Toxicology

At systemic and local levels, ibopamine has been proved to be of low toxicity. It is well tolerated since no obvious changes to the haematological and behavioural parameters have been observed after administration.[ citation needed ] Ibopamine eye drop at 2% concentration, containing 1 mg of the compound, did not show any significant systemic side-effects and tachyphylaxis phenomena whereas the oral dosage is higher than 400 mg per day. [6]

Clinical Use

A fast and short-lasting mydriasis can be induced by ibopamine without systemic side-effects.

See also

Related Research Articles

<span class="mw-page-title-main">Glaucoma</span> Group of eye diseases

Glaucoma is a group of eye diseases that result in damage to the optic nerve and cause vision loss. The most common type is open-angle glaucoma, in which the drainage angle for fluid within the eye remains open, with less common types including closed-angle glaucoma and normal-tension glaucoma. Open-angle glaucoma develops slowly over time without pain. Peripheral vision may begin to decrease, followed by central vision, resulting in blindness if not treated. Closed-angle glaucoma can present gradually or suddenly. The sudden presentation may involve severe eye pain, blurred vision, mid-dilated pupil, redness of the eye, and nausea. Vision loss from glaucoma, once it has occurred, is permanent. Eyes affected by glaucoma are referred to as being glaucomatous.

<span class="mw-page-title-main">Trifluoperazine</span> Chemical compound

Trifluoperazine, marketed under the brand name Stelazine among others, is a typical antipsychotic primarily used to treat schizophrenia. It may also be used short term in those with generalized anxiety disorder but is less preferred to benzodiazepines. It is of the phenothiazine chemical class. It was approved for medical use in the United States in 1959.

<span class="mw-page-title-main">Beta blocker</span> Class of medications used to manage abnormal heart rhythms

Beta blockers, also spelled β-blockers, are a class of medications that are predominantly used to manage abnormal heart rhythms (arrhythmia), and to protect the heart from a second heart attack after a first heart attack. They are also widely used to treat high blood pressure, although they are no longer the first choice for initial treatment of most patients.

<span class="mw-page-title-main">Cyclopentolate</span> Pair of enantiomers

Cyclopentolate is a muscarinic antagonist. It is commonly used as an eye drop during pediatric eye examinations to dilate the eye (mydriatic) and prevent the eye from focusing/accommodating (cycloplegic). Cyclopentolate or atropine can also be administered to reverse muscarinic and central nervous system effects of indirect cholinomimetic (anti-AChase) administration.

<span class="mw-page-title-main">Cabergoline</span> Chemical compound

Cabergoline, sold under the brand name Dostinex among others, is a dopaminergic medication used in the treatment of high prolactin levels, prolactinomas, Parkinson's disease, and for other indications. It is taken by mouth.

<span class="mw-page-title-main">Betaxolol</span> Chemical compound

Betaxolol is a selective beta1 receptor blocker used in the treatment of hypertension and angina. Being selective for beta1 receptors, it typically has fewer systemic side effects than non-selective beta-blockers, for example, not causing bronchospasm as timolol may. Betaxolol also shows greater affinity for beta1 receptors than metoprolol. In addition to its effect on the heart, betaxolol reduces the pressure within the eye. This effect is thought to be caused by reducing the production of the liquid within the eye. The precise mechanism of this effect is not known. The reduction in intraocular pressure reduces the risk of damage to the optic nerve and loss of vision in patients with elevated intraocular pressure due to glaucoma.

<span class="mw-page-title-main">Latanoprost</span> Chemical compound

Latanoprost, sold under the brand name Xalatan among others, is a medication used to treat increased pressure inside the eye. This includes ocular hypertension and open angle glaucoma. It is applied as eye drops to the eyes. Onset of effects is usually within four hours, and they last for up to a day.

<span class="mw-page-title-main">Carvedilol</span> Oral blood-pressure medication

Carvedilol, sold under the brand name Coreg among others, is a medication used to treat high blood pressure, congestive heart failure (CHF), and left ventricular dysfunction in people who are otherwise stable. For high blood pressure, it is generally a second-line treatment. It is taken by mouth.

<span class="mw-page-title-main">Brimonidine</span> Chemical compound

Brimonidine is a medication used to treat open-angle glaucoma, ocular hypertension, and rosacea. In rosacea it improves the redness. It is used as eye drops or applied to the skin.

<span class="mw-page-title-main">4-Hydroxyamphetamine</span> Group of stereoisomers

4-Hydroxyamphetamine (4HA), also known as hydroxyamfetamine, hydroxyamphetamine, oxamphetamine, norpholedrine, para-hydroxyamphetamine, and α-methyltyramine, is a drug that stimulates the sympathetic nervous system.

<span class="mw-page-title-main">Apraclonidine</span> Chemical compound

Apraclonidine (INN), also known under the brand name Iopidine, is a sympathomimetic used in glaucoma therapy. It is an α2 adrenergic receptor agonist and a weak α1 adrenergic receptor agonist.

<span class="mw-page-title-main">Levobetaxolol</span> Chemical compound

Levobetaxolol is a drug used to lower the pressure in the eye in treating conditions such as glaucoma. It is marketed as a 0.25 or 0.5% ophthalmic solution of levobetaxolol hydrochloride under the trade name Betaxon. Levobetaxolol is a beta-adrenergic receptor inhibitor.

<span class="mw-page-title-main">Dopexamine</span> Chemical compound

Dopexamine is a synthetic analogue of dopamine that is administered intravenously in hospitals to reduce exacerbations of heart failure and to treat heart failure following cardiac surgery. It is not used often, as more established drugs like epinephrine, dopamine, dobutamine, norepinephrine, and levosimendan work as well. It works by stimulating beta-2 adrenergic receptors and peripheral dopamine receptor D1 and dopamine receptor D2. It also inhibits the neuronal re-uptake of norepinephrine.

Brimonidine/timolol, sold under the brand name Combigan among others, is a fixed-dose combination medication eye drop used for the treatment of glaucoma. It is a combination of brimonidine and timolol.

<span class="mw-page-title-main">Deoxyepinephrine</span> Chemical compound

Deoxyepinephrine, also known by the common names N-methyldopamine and epinine, is an organic compound and natural product that is structurally related to the important neurotransmitters dopamine and epinephrine. All three of these compounds also belong to the catecholamine family. The pharmacology of epinine largely resembles that of its "parent", dopamine. Epinine has been found in plants, insects and animals. It is also of significance as the active metabolic breakdown product of the prodrug ibopamine, which has been used to treat congestive heart failure.

<span class="mw-page-title-main">Alpha blocker</span> Class of pharmacological agents

Alpha-blockers, also known as α-blockers or α-adrenoreceptor antagonists, are a class of pharmacological agents that act as antagonists on α-adrenergic receptors (α-adrenoceptors).

<i>N</i>,<i>N</i>-Dimethyldopamine Chemical compound

N,N-Dimethyldopamine (DMDA) is an organic compound belonging to the phenethylamine family. It is related structurally to the alkaloid epinine (N-methyldopamine) and to the major neurotransmitter dopamine (of which it is the N,N-dimethylated analog). Because of its structural relationship to dopamine, DMDA has been the subject of a number of pharmacological investigations. DMDA has been detected in Acacia rigidula.

Ripasudil, a derivative of fasudil, is a rho kinase inhibitor drug used for the treatment of glaucoma and ocular hypertension.

<span class="mw-page-title-main">Dopamine (medication)</span> Hormone used as a medication

Dopamine, sold under the brandname Intropin among others, is a medication most commonly used in the treatment of very low blood pressure, a slow heart rate that is causing symptoms, and, if epinephrine is not available, cardiac arrest. In newborn babies it continues to be the preferred treatment for very low blood pressure. In children epinephrine or norepinephrine is generally preferred while in adults norepinephrine is generally preferred for very low blood pressure. It is given intravenously or intraosseously as a continuous infusion. Effects typically begin within five minutes. Doses are then increased to effect.

Autonomic drugs can either inhibit or enhance the functions of the parasympathetic and sympathetic nervous systems. This type of drug can be used to treat a wide range of diseases, such as glaucoma, asthma, urinary, gastrointestinal and cardiopulmonary disorders.

References

  1. Magacho L, Costa ML, Dessimoni A, de Avila MP (2006). "Comparison between the 1% and 2% ibopamine provocative test in primary open-angle glaucoma patients: sensitivity, specificity and tolerability". Arquivos Brasileiros De Oftalmologia. 69 (5): 695–699. doi: 10.1590/S0004-27492006000500015 . PMID   17187138.
  2. Marchini G, Babighian S, Tosi R, Perfetti S, Bonomi L (June 2001). "Effects of 2% ibopamine on pupil, refraction, anterior segment anatomy and intraocular pressure". Journal of Ocular Pharmacology and Therapeutics. 17 (3): 215–223. doi:10.1089/108076801750295254. PMID   11436942.
  3. van Veldhuisen DJ, Man in 't Veld AJ, Dunselman PH, Lok DJ, Dohmen HJ, Poortermans JC, et al. (November 1993). "Double-blind placebo-controlled study of ibopamine and digoxin in patients with mild to moderate heart failure: results of the Dutch Ibopamine Multicenter Trial (DIMT)". Journal of the American College of Cardiology. 22 (6): 1564–1573. doi:10.1016/0735-1097(93)90579-P. PMID   7901256.
  4. Metra M, Missale C, Spano PF, Cas LD (May 1995). "Dopaminergic drugs in congestive heart failure: hemodynamic and neuroendocrine responses to ibopamine, dopamine, and dihydroergotoxine". Journal of Cardiovascular Pharmacology. 25 (5): 732–740. doi: 10.1097/00005344-199505000-00008 . PMID   7630152. S2CID   37607224.
  5. Lieverse AG, Girbes AR, Van Veldhuisen DJ, Smit AJ, Zijlstra JG, Meijer S, et al. (July 1995). "The effects of ibopamine on glomerular filtration rate and plasma norepinephrine remain preserved during prolonged treatment in patients with congestive heart failure". European Heart Journal. 16 (7): 937–942. doi:10.1093/oxfordjournals.eurheartj.a061028. PMID   7498209.
  6. 1 2 3 Giuffre I (2007). "Ibopamine stimulates α-adrenergic receptors and D1 dopaminergic receptors in the eye". Current Drug Therapy. 2 (2): 127–132. doi:10.2174/157488507780619112.
  7. Casagrande C, Santangelo F, Saini C, Doggi F, Gerli F, Cerri O (February 1986). "Synthesis and chemical properties of ibopamine and of related esters of N-substituted dopamines--synthesis of ibopamine metabolites". Arzneimittel-Forschung. 36 (2A): 291–303. PMID   3707640.
  8. Soldati L, Gianesello V, Galbiati I, Gazzaniga A, Virno M (February 1993). "Ocular pharmacokinetics and pharmacodynamics in rabbits of ibopamine, a new mydriatic agent". Experimental Eye Research. 56 (2): 247–254. doi:10.1006/exer.1993.1032. PMID   8096462.
  9. Rajfer SI, Rossen JD, Douglas FL, Goldberg LI, Karrison T (April 1986). "Effects of long-term therapy with oral ibopamine on resting hemodynamics and exercise capacity in patients with heart failure: relationship to the generation of N-methyldopamine and to plasma norepinephrine levels". Circulation. 73 (4): 740–748. doi: 10.1161/01.CIR.73.4.740 . PMID   3948372.
  10. Ugahary LC, Ganteris E, Veckeneer M, Cohen AC, Jansen J, Mulder PG, van Meurs JC (March 2006). "Topical ibopamine in the treatment of chronic ocular hypotony attributable to vitreoretinal surgery, uveitis, or penetrating trauma". American Journal of Ophthalmology. 141 (3): 571–573. doi:10.1016/j.ajo.2005.09.034. PMID   16490513.
  11. Soldati L, Gianesello V, Galbiati I, Gazzaniga A, Virno M (February 1993). "Ocular pharmacokinetics and pharmacodynamics in rabbits of ibopamine, a new mydriatic agent". Experimental Eye Research. 56 (2): 247–254. doi:10.1006/exer.1993.1032. PMID   8096462.
  12. De Gregorio F, Pecori Giraldi J, Pannarale L, Saccucci S, Virno M (1996-01-01). "Ibopamine in glaucoma diagnostics: a new pharmacological provocative test". International Ophthalmology. 20 (1–3): 151–155. doi:10.1007/BF00212962. PMID   9112180. S2CID   24889922.